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ABSTRACT
Introduction: Management of patent ductus
arteriosus (PDA) in preterm infants is one of the most
controversial topics in neonatal medicine. The
availability of different pharmacotherapeutic options
often poses a practical challenge to the practising
neonatologist as to which one to choose as a
therapeutic option. Our objectives are to determine the
relative merits of the available pharmacotherapeutic
options for the management of PDA.
Methods and Analysis: We will conduct a
systematic review of all randomised controlled trials
evaluating the use of intravenous or oral:
indomethacin, ibuprofen and acetaminophen for the
treatment of PDA in preterm infants. The primary
outcome is failure of closure of the PDA. Secondary
outcomes are neonatal mortality, need for surgical
closure, duration of ventilator support, chronic lung
disease, intraventricular haemorrhage, periventricular
leukomalacia, necrotising enterocolitis, gastrointestinal
bleeding, time to full enteral feeds and oliguria. We will
search Medline, Embase and Cochrane Central Register
of Controlled Trials (CENTRAL) as well as grey
literature resources. Two reviewers will independently
screen titles and abstracts, review full texts, extract
information, and assess the risk of bias (ROB) and the
confidence in the estimate (with Grading of
Recommendations Assessment, Development and
Evaluation (GRADE) approach). Subgroup analysis
according to gestational age, birth weight, different
doses of interventions, time of administration of the
first dose of the intervention, and echocardiographic
definition of haemodynamically significant PDA and
ROB are planned. We will perform a Bayesian network
meta-analysis to combine the pooled direct and
indirect treatment effect estimates for each outcome, if
adequate data are available.
Ethics and Dissemination: The results will help to
reduce the uncertainty about the safety and effectiveness
of the interventions, will identify knowledge gaps or will
encourage further research for other therapeutic options.
Therefore, its results will be disseminated through peer-
reviewed publications and conference presentations. On
the basis of the nature of its design, no ethics approval
is necessary for this study.
Trial registration number: CRD42015015797.
INTRODUCTION
One of the most common cardiovascular
problems that prematurely born infants
experience early in life is patent ductus arter-
iosus (PDA). The ductus arteriosus is a blood
vessel that connects the two major arteries,
namely the aorta and the pulmonary artery,
and is essential in maintaining circulation in
fetal life.1 After the baby is born and the
fetal circulation changes to adult circulation,
the ductus arteriosus functionally closes
between 18 and 24 hours of life.1 However,
in babies born prematurely, the ductus arter-
iosus often fails to close spontaneously and
leads to a number of morbidities. It has been
Strengths and limitations of this study
▪ This systematic review and network meta-ana-
lysis will assess the effectiveness and safety of
the interventions used to treat haemodynamically
significant patent ductus arteriosus in preterm
infants. It will be the first network meta-analysis
to assess the comparative effectiveness of
ibuprofen, paracetamol and indomethacin.
▪ Among additional strengths, this review will be
based on a comprehensive search strategy,
broad inclusion criteria and will use the Grading
of Recommendations Assessment, Development
and Evaluation (GRADE) approach to assess the
certainty of the evidence.
▪ This study will, in addition to the traditional early
outcomes during the hospitalisation, search for
evidence related to long-term neurodevelop-
mental outcomes.
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shown that in infants born with a birth weight of
<1000 g, the ductus arteriosus remains open in 66% of
infants beyond the ﬁrst week of life. In the extreme pre-
mature population born at 24 weeks of gestation, only
13% of infants are found to have their ductus closed by
the end of the ﬁrst week.2 This makes PDA an important
issue from the clinical management perspective in the
ﬁrst few days of life in preterm infants. Management of
PDA in preterm infants is one of the most controversial
topics in neonatal medicine. It is associated with a
number of comorbidities such as necrotising enterocoli-
tis (NEC), bronchopulmonary dysplasia and intraventri-
cular haemorrhage (IVH).3–5 The management
controversy has mainly focused on when to treat and
with what to treat. To increase the complexity of matters,
these two aspects of PDA management are not mutually
exclusive, with the modality of treatment often being dic-
tated by the timing of treatment. There have been a
large number of published studies, meta-analyses and
editorials focusing on different aspects of manage-
ment.6–8 Regarding the timing of treatment, prophylac-
tic therapy has gradually fallen out of favour and
neonatal units have shifted towards a more conservative
approach by treating only the clinically and echocardio-
graphically (ECHO) signiﬁcant PDA.6 However, the big
dilemma that still persists among neonatologists is what
to use as the primary modality of treatment.
Indomethacin, which is a prostaglandin inhibitor, has
been traditionally used as the ﬁrst-line treatment for
PDA. However, owing to its potent vasoconstrictive
effect, it has been found to be associated with brain
white matter injury, NEC, intestinal perforation, renal
impairment and platelet dysfunction.7–11 Hence, ibupro-
fen was later introduced as a treatment modality, which
promised to have a lesser vasoconstrictive effect on
end-organ microcirculation.12 Nevertheless, it has also
been associated with some renal effects along with pul-
monary hypertension and hyperbilirubinemia.13–15 More
recently, acetaminophen has been used as an additional
effective treatment for PDA without any signiﬁcant
adverse effects reported.16 17
Randomised controlled trials (RCTs) comparing indo-
methacin with placebo, as well as oral and intravenous
ibuprofen with placebo, have been conducted. The most
recent Cochrane review on the use of ibuprofen for
PDA has combined the aforementioned studies into a
comprehensive meta-analysis which showed that ibupro-
fen was much safer compared with indomethacin in
terms of incidence of NEC and oliguria, without any dif-
ference in efﬁcacy.12 Meanwhile, acetaminophen has
been compared with oral ibuprofen in two RCTs, evi-
dence that has been summarised in a recent Cochrane
systematic review,18 which again showed no difference in
efﬁcacy between the two drugs.
The availability of different pharmacotherapeutic
options often poses a practical challenge to the practis-
ing neonatologist as to which one to choose as a thera-
peutic option. As the number of available treatment
options increases, the required number of pairwise sys-
tematic reviews would increase exponentially. Pairwise
meta-analysis of multiple treatments is laborious and
time-consuming. In addition, the newer pharmacothera-
peutic agents such as acetaminophen have not been
compared with placebo. This may lead to a dilemma in
choosing the safest and the most effective therapeutic
option. Newer agents compared head to head in recent
RCTs show no statistically signiﬁcant difference in effect-
iveness.19 This lack of difference may be attributed to
the fact that either the studies may have had an insufﬁ-
cient number of participants or there were methodo-
logical ﬂaws in the trials.
The use of network meta-analysis (NMA) allows the
comparison of the efﬁcacy and important safety proﬁles
of the different pharmacotherapeutic options for PDA
closure that are available. The Cochrane handbook con-
siders NMA as a highly valuable tool to evaluate and
rank treatment options according to their safety and
effectiveness.20 Bayesian NMA has been proposed as an
effective method for evaluating the effectiveness of mul-
tiple treatment comparisons.21 22 To the best of our
knowledge, there is one previous NMA conducted by
Jones et al23 in 2011 comparing indomethacin, ibupro-
fen and placebo using a frequentist approach. However,
more evidence regarding ibuprofen and indomethacin
has been generated since then, as well as the advent of
evidence about acetaminophen, showing that it could be
a promising alternative.18 Therefore, we decided to
conduct a systematic review and NMA using a Bayesian
approach comparing all the pharmacological treatments
for PDA in preterm infants to determine their relative
effectiveness and safety in relation to one another.
OBJECTIVE
We aim to determine the comparative effectiveness and
safety of the available pharmacological treatments for
PDA in preterm infants. For this purpose, we will use a
Bayesian NMA.
METHODS AND DESIGN
This systematic review and NMA protocol has been regis-
tered on the PROSPERO international prospective regis-
ter of systematic reviews (CRD42015015797).This
protocol was developed following the Preferred
Reporting Items for Systematic Review and Meta-Analysis
Protocols (PRISMA-P) guidance.24 The ﬁnal report will
comply with the recommendations of the PRISMA
Extension Statement for Reporting of Systematic Reviews
Incorporating Network Meta-analyses of Health Care
Interventions.25
Search strategy
We will search from their conception to August 2016 the
following databases: Medline and Embase through the
Ovid platform, and Cochrane Central Register of
Controlled Trials (CENTRAL). We will use a
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combination of controlled terms (Medical Subject
Heading (MeSH) and Emtree), and free-text terms with
various synonyms for PDA, indomethacin, ibuprofen
and acetaminophen. We will use the validated RCTs
ﬁlters created by McMaster University Health
Information Research Unit for Medline and Embase
through the Ovid platform.26 Search alerts will be set up
for monthly notiﬁcation and the search will be repeated
before the ﬁnal manuscript submission to identify any
new relevant trials. Search strategies have been devel-
oped with liaison with an experienced librarian at
McMaster University Library. No language, publication
status or date limit will be used. An example for the
search strategy for Medline through Ovid is detailed in
online supplementary appendix A.
We will seek registered details of selected trials in the
US National Institutes of Health resource (http://www.
clinicaltrials.gov) and the WHO International Clinical
Trials Registry Platform Search Portal. We intend to
obtain additional grey literature from personal commu-
nication from experts in the ﬁeld, reviewing the refer-
ence lists of relevant articles, abstracts and conference
proceedings (Society for Pediatric Research, European
Society for Pediatric Research) and seeking results of
unpublished trials. We intend to contact authors of
unpublished work and authors of published trials in
order to clarify information when necessary.
Eligibility criteria
We will include RCTs and quasi-RCTs that evaluate the
effectiveness or safety of treatments for the PDA. Studies
will have to have the following characteristics: (1) partici-
pants: preterm infants <37 weeks gestational age or low
birthweight infants (<2500 g) with a PDA diagnosed clini-
cally or ECHO in the neonatal period (<28 days of life);
(2) interventions: indomethacin, ibuprofen, acetamino-
phen or other cyclo-oxygenase inhibitors. We will
include studies that used any of the interventions regard-
less of the dose and method of administration (intraven-
ously or orally); and (3) outcomes: our primary
outcome will be the failure of permanent PDA closure
within a week of administration of the ﬁrst dose of the
intervention. The secondary outcomes are other mea-
sures of effectiveness, such as mortality, need for add-
itional courses or doses of the intervention, surgical
treatment and reopening of the ductus, as well as safety
outcomes. All the outcomes, their deﬁnitions and their
measures are detailed in table 1.
We will exclude studies of infants with congenital
structural heart disease or other congenital anomalies.
The trial has included some infants with heart disease,
and the authors report the results separately in infants
with and without heart disease, we will use the latter for
the analysis. In case they do not report results separately,
we will include the study if we have information about
the proportion of infants with these diseases, and this is
<30% of the total population. We will exclude studies in
which the intervention was surgical treatment.
Study selection
The titles and abstracts retrieved will be screened by two
independent reviewers to assess their eligibility (SM, IDF,
MET or DA). As a second step, the full-text articles of
the potentially eligible studies will be screened to assess
their eligibility. We will include the full text of all studies
for which both reviewers agree about their inclusion.
Any disagreements between the reviewers will be
resolved by discussion and if no agreement can be
reached, a third member of the team (IDF or SM) will
decide whether the study shall be included or not. We
will refer to inclusion and exclusion criteria during the
screening process. Records of ineligible full-text articles
along with the reason for ineligibility will be saved for
future reference. We will present the PRISMA ﬂow
diagram27 demonstrating the search and screening
process. We will contact authors of primary studies,
during screening, to provide any missing information
that may inﬂuence eligibility.
A pretested and standardised Microsoft Excel data
extraction form will be used to extract the data from the
eligible studies. Data items to be extracted include: (1)
publication year, (2) mean gestational age, (3) mean
birth weight (4) number of infants randomised, (5)
number of losses to follow-up, (6) mode and doses of
treatment, (7) any co-interventions during treatment,
(8) continuous and dichotomous outcome measures
and (9) adverse effects (neurological, renal, haemato-
logical, hepatic and gastrointestinal effects). The data
extraction form will be pilot tested independently by all
reviewers before its use, to standardise the process. Four
reviewers (SM, IDF, MET and DA) will carry out the
extraction, working independently in pairs. In case of
disagreement in assessing the methodological quality of
the study, we will try to resolve it by consensus. If consen-
sus cannot be reached, a third designated reviewer (IDF
or SM) will be invited to arbitrate.
Assessment of risk of bias (ROB)
The ROB of eligible studies will be assessed according to
a modiﬁed version of the Cochrane Collaboration’s ROB
tool.20 The criteria to be assessed are sequence gener-
ation, allocation concealment, blinding of participants,
personnel and outcome assessors, completeness of
follow-up, selective outcome reporting and presence of
other biases. Each domain will be assigned a score ‘deﬁn-
itely low risk’, or ‘deﬁnitely high risk’ or ‘unclear risk’.
We will further categorise the ‘unclear risk’ to ‘ probably
low risk’ or ‘probably high risk’.28 Two independent
reviewers (SM, IDF, MET or DA) will assess the ROB. We
will try to reach consensus in case of disagreement
between two reviewers when assessing the methodological
quality of the studies. Nevertheless, if consensus cannot
be reached, a third reviewer (IDF or SM) will resolve it.
Direct comparisons and assessment of heterogeneity
We will ﬁrst describe the results narratively and, where
possible, the direct evidence will be pooled. Given that
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we expect clinical and methodological heterogeneity
among the studies (see Rating the conﬁdence in esti-
mates of the effect section), which in turn will create
statistical heterogeneity, we will pool direct evidence for
each treatment comparison using a random-effects (RE)
model. In comparison to the ﬁxed-effect (FE) model,
the RE model is conservative in the sense that it
accounts for both within-study and between-study vari-
ability. The RE model assumes that the observed treat-
ment effect for a study is a combination of a treatment
effect common to all studies plus a component speciﬁc
to that study alone.29 30
We will pool the outcome data using a Bayesian RE
model.31 Effect estimates along with 95% credible inter-
vals (CrIs) will be estimated using OR for binary out-
comes, and mean difference (MD) for continuous
outcomes, if they are reported using the same scale, or
standardised MD (SMD) otherwise (see table 1). For
studies with binary outcomes, we will add 0.5 to each
cell if one arm is zero, whereas we will exclude studies
from the analyses with zero events in both arms. We will
use non-informative priors for all model parameters
apart from the heterogeneity variance parameter, for
which we will use the informative prior suggested by
Turner et al32 and Rhodes et al.33 All Bayesian analyses
will be performed using the Markov chain Monte Carlo
method.
We will assess heterogeneity by estimating the magni-
tude of the between-study variance using the empirical
distribution as estimated by Turner et al32 and Rhodes
et al,33 and by using the I2 statistic to quantify the per-
centage of variability that is due to true differences
between studies rather than a sampling error.34 35 We
will interpret the I2 statistic using the thresholds set
forth by the Cochrane Collaboration.20 In case there is
important heterogeneity, we will use meta-regression to
explain it, if we have enough data to do so. Otherwise,
we will perform subgroup analyses.
We propose, a priori, the following potential sources
of heterogeneity, which could be possible effect modi-
ﬁers: gestational age (<28; 28–32; >32 weeks of gestational
age), birth weight (<1000; 1000–1500; >1500 g), differ-
ent doses of the interventions, time of administration of
the ﬁrst dose of the intervention (<3, 3–7, >7 days),
Table 1 Characteristics of the outcome measures
Outcome Measurement of variable (units)
Statistical estimates and
measurement of association
Primary
Failure to close the PDA Failure to closure of the PDA. We will emphasise on closure
definition within a week of administration of the first dose of
the intervention (PDA diagnosed either clinically or by ECHO
criteria), but we will use the time defined by authors to
analyse the outcome accordingly.
OR (95% CrI)
Secondary
General outcomes
–Neonatal mortality Death during the first 28 days of life. OR (95% CrI)
–Reopening of the ductus
arteriosus
Number of neonates with echocardiographic determination of
reopening of the ductus.
–Need for surgical closure
of the PDA
Number of neonates who required surgical treatment of the
PDA.
–CLD Total number of neonates with oxygen requirement at
28 days postnatal age in addition to compatible clinical and
roentgenographic findings.
Neurological effects
–IVH Number of neonates with IVH (I–IV). OR (95% CrI)
–Severe IVH Number of neonates with severe IVH.
–PVL Number of neonates with PVL.
–Neurodevelopmental
disability
Number of children with any reported disability at 1–2 years
of age (eg, motor, cognitive, sensory impairments).
Gastrointestinal and nutritional effects
– Intestinal perforation
– GB
– NEC
– Time to full enteral feeds
▸ Number of neonates with Intestinal perforation.
▸ Number of neonates with GB.
▸ Number of neonates with NEC (any stage).
▸ Postnatal age at time of achieving full enteral feeds.
▸ OR (95% CrI)
▸ OR (95% CrI)
▸ MD (95% CrI)
▸ OR (95% CrI)
Renal effects
– Decreased urine output Number of neonates with urine output, defined as <1 cc/kg/
hour.
▸ OR (95% CrI)
CLD, chronic lung disease; ECHO, echocardiographically; GB, gastrointestinal bleed; IVH, intraventricular haemorrhage; MD, mean
difference; NEC, necrotising enterocolitis; PDA, patent ductus arteriosus; PVL, periventricular leukomalacia.
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echocardiographic ﬁndings (PDA size and left atrium:
aortic root ratio), time of PDA assessment post pharma-
cotherapy (<24 hours, 24 hours to 3 days, and >7 days)
and previous medical PDA medical therapy. We hypo-
thesise that lower gestational age, lower birth weight,
lower doses, more time from diagnosis to administration
of the intervention, the echocardiographic ﬁndings of
increased PDA size and increased left atrium:aortic root
ratio, and previous medical therapy will be related to a
lower treatment effect. We will either perform meta-
regression or subgroup analyses as appropriate using
these hypotheses as the study level covariates and we will
perform a sensitivity analysis based on the studies with
high ROB and based on studies based on patients that
had clinical diagnosis of the PDA.
Assessment of reporting bias
We will construct a funnel plot for each treatment com-
parison and outcome to assess the potential publication
bias and small-study effects,36 if we retrieve at least 10
studies.20 Visual inspection to determine the funnel
asymmetry will be used for this purpose, as well as Begg
and Mazumdar37 rank correlation and Egger et al’s
test.36
Network meta-analysis
Given that many of the treatment combinations available
to treat PDA have not been compared in head-to-head
studies, we expect that some of the possible comparisons
between the interventions will not have direct evidence.
Hence, we will perform a Random-Effects NMA, if the
assumptions of between-study homogeneity, transitivity
and coherence across treatment comparisons are judged
to be justiﬁable. In the absence of direct evidence for a
given comparison, an indirect comparison will provide
an estimate of the treatment effect. In the presence of
direct evidence, the NMA will provide a combined esti-
mate (ie, direct and indirect evidence).38 For instance,
in a triangular network ABC composed by studies that
directly compare A versus B and A versus C treatments,
we can indirectly estimate the effect of B versus C treat-
ments. In case direct evidence of B versus C treatment
comparison is also available, then a combined estimate
of direct and indirect evidence of B versus C can be cal-
culated using an NMA.
Evidence from an NMA may be inconsistent if the
direct and indirect evidence is incompatible (loop
inconsistency) or the studies involving one of the treat-
ments are fundamentally different from the studies
involving another treatment (design inconsistency). In
order to evaluate both design and loop inconsistency, we
will apply the design-by-treatment interaction model,
and if this suggests inconsistency, then we will apply the
loop-speciﬁc method to assess local inconsistency.39–41
We will perform a network meta-regression or subgroup
analysis using the same potential treatment effect modi-
ﬁers described in the Direct comparisons and assess-
ment of heterogeneity section to explore important
heterogeneity or inconsistency. We will also perform sen-
sitivity analysis for different heterogeneity prior to asses-
sing the robustness of results.31–33
For each outcome, we will present the network
diagram and a forest plot with the network estimates.
Effect estimates will be presented along with their corre-
sponding 95% CrI, as well as their 95% predictive inter-
val (PrI) representing the interval within which we
would expect the treatment effect of a future study to
lie.42 43 We will rank the probabilities with their 95%
CrIs as well as the Surface Under the Cumulative
RAnking curve (SUCRA) values and cumulative prob-
ability rankograms.44 SUCRA values range from 0% to
100% and it is expected that the best treatments will
have high SUCRA values.
We will ﬁt a Bayesian hierarchical model with non-
informative priors adjusting for correlation of multiarm
trials, and assuming a common within-network hetero-
geneity variance. Series of 100 000 simulations will be
used to allow convergence, and after thinning of 10 and
discarding the ﬁrst 20 000 simulations we will produce
the outputs. We will assess model convergence on the
basis of the Gelman and Rubin45 diagnostic test. The
analysis will be performed in OpenBUGs (V.3.2.3).46
Rating the confidence in estimates of the effect
We will assess the conﬁdence in the estimates for each
outcome using the Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
approach.47 For this purpose, two authors will independ-
ently do the assessment (SM, IDF, MET or DA). The
conﬁdence in the estimates will be based on four levels:
high, moderate, low and very low. For the direct compar-
isons, we will assess and rate each outcome based on the
categories: ROB, imprecision, inconsistency and publica-
tion bias.48–52
We will assess and rate the conﬁdence in all the indir-
ect comparisons—if available—obtained from ﬁrst-order
loops (FOLs) following the GRADE categories used
for assessing the direct comparisons in addition to the
transitivity assessment. Transitivity, also called similarity,53
is the assumption that an indirect comparison is a
valid method to compare two treatments that have not
been compared in a head-to-head trial, because the
studies are sufﬁciently similar in important clinical and
methodological characteristics or, in other words, that
they are similar in their distributions of effect modi-
ﬁers.54 55 Then, when both types of evidence (direct and
indirect) are present, we will rate the conﬁdence in each
NMA effect estimate using the higher rating of them.
We will assess and rate the conﬁdence in estimates of
effect from the direct comparisons in our pairwise
meta-analyses described previously. In order to rate the
conﬁdence in the indirect comparisons, we will focus
our assessments on FOLs, that is, loops connected to the
interventions of interest through only one other inter-
vention. For instance, if for A, B and C interventions
there are direct comparisons of A versus B (AB) and B
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versus C (BC), we will be able to indirectly estimate the
effects of A versus C (AC). The AC will be a FOL. We
will choose FOL with the lowest variances, and thus con-
tribute the most to the estimates of effect, for rating the
conﬁdence.
Within FOLs, the indirect comparison conﬁdence will
be the lowest of the conﬁdence ratings we have assigned
to the contributing direct comparisons. For example, if
we ﬁnd that AB has moderate conﬁdence and BC has
high conﬁdence, we will judge the associated indirect
comparison, AC, as moderate conﬁdence. We may rate
down conﬁdence in the indirect comparisons further if
we have a strong suspicion that the transitivity assump-
tion has been violated.
Our overall judgement of conﬁdence in the NMA esti-
mate for any pairwise comparison will be the higher of
the conﬁdence rating among the contributing direct
and indirect comparisons. However, we may rate down
conﬁdence in the network estimate if we ﬁnd that the
direct and indirect estimates have inconsistency. For this
purpose, the GRADE approach recommends assessing
the incoherence (or inconsistency as described in the
Network meta-analysis section) criteria, which is deﬁned
as the differences between direct and indirect estimates
of effect.56
DISCUSSION
The present systematic review will provide evidence of
comparative effectiveness and safety of the medical treat-
ments for the closure of PDA in preterm babies. To the
best of our knowledge, this will be the ﬁrst review that
will include the three available medical drugs. Its results
will be of interest to a broad audience: practice guide-
line developers, paediatricians, neonatologists, policy-
makers and researchers, because it could be used to give
clinical recommendations for infants with PDA, and will
also identify gaps in knowledge that could be the subject
of future research.
Our review will have several methodological strengths.
First, we will implement a wide comprehensive search
that will include published work in the most comprehen-
sive databases, as well as unpublished work. Second, we
will use the novel method for rating the conﬁdence in
the estimates recommended by the GRADE working
group. Third, our review will take into account the birth
weight and gestational age and other potential sources of
heterogeneity. Finally, we will pool the results using a
Bayesian framework, which will provide probability distri-
butions that will summarise the likely values for the treat-
ment effect of each intervention relative to each other.57
On the other hand, some challenges for this review
exist. We anticipate some degree of clinical heterogeneity
with regard to the possible sources that we described.
Finally, if the extent of included studies is small, the
ability to explore heterogeneity may be limited.
We hope that this review will provide evidence to
reduce the uncertainty about the ranking of the
interventions in terms of effectiveness and safety,
improve neonatal care, and encourage further research
for other therapeutic options for the treatment of PDA
in preterm infants.
Ethics and dissemination
No ethical approval is required; this review is a study
based on the analysis of published evidence. No per-
sonal data of patients were required. The results of the
review will be submitted to a peer-reviewed journal
focusing on paediatrics or neonatology ﬁelds for publi-
cation. We also plan to present results in future
conferences.
Glossary of terms Direct estimates: Estimate provided
by a head-to-head comparison. Indirect estimate:
Estimate provided by two or more head-to-head compar-
isons that share a common comparator (eg, direct com-
parisons: AB and BC, indirect estimation: AC). Network
meta-analysis (NMA): Combination of direct (when
available) and indirect estimates of a comparison.
Loops: Two or more head-to-head comparisons that con-
tribute to an indirect estimate. First-order loops (FOLs)
are those loops that involve only a single additional
intervention. Heterogeneity: Differences in estimates of
effect across studies that assessed the same comparison.
Inconsistency:56 The GRADE approach criterion for
rating the degree of consistency among the results in
the meta-analysis (heterogeneity). Incoherence:56 The
GRADE approach term used as criterion for rating the
inconsistency, speciﬁcally in NMA. It refers to the differ-
ences between direct and indirect estimates of effect.
Intransitivity:56 Differences in study characteristics that
may modify treatment effect in the direct comparisons,
and could bias the indirect estimate.
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